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Strategies to elicit Abs that can neutralize diverse strains of a
highly mutable pathogen are likely to result in a potent vaccine.
Broadly neutralizing Abs (bnAbs) against HIV have been isolated
from patients, proving that the human immune system can evolve
them. Using computer simulations and theory, we study immuni-
zation with diverse mixtures of variant antigens (Ags). Our results
show that particular choices for the number of variant Ags and the
mutational distances separating them maximize the probability of
inducing bnAbs. The variant Ags represent potentially conflicting
selection forces that can frustrate the Darwinian evolutionary
process of affinity maturation. An intermediate level of frustration
maximizes the chance of evolving bnAbs. A simple model makes
vivid the origin of this principle of optimal frustration. Our results,
combined with past studies, suggest that an appropriately chosen
permutation of immunization with an optimally designed mixture
(using the principles that we describe) and sequential immunization
with variant Ags that are separated by relatively large mutational
distances may best promote the evolution of bnAbs.
HIV | broadly neutralizing antibodies | statistical mechanics |
evolutionary biology | biophysics
Vaccination has saved more lives than any other medicalintervention, but some pathogens have evolved to defy the
empirical immunization paradigms pioneered by Jenner and Pasteur.
These pathogens often share two characteristics: they present
themselves in diverse guises (e.g., by being highly mutable), and they
hide from or degrade the immune system. HIV is a prominent
example of a pathogen with these traits.
More than 30 y into the HIV/AIDS epidemic, no widely ef-
fective vaccine has yet been developed. Among many obstacles,
the most difficult to confront may be the ability of HIV to evolve
rapidly and create an enormous diversity of mutated viral strains,
thereby evading vaccine-induced immune responses directed at only
a few strains. A potent vaccine will likely need to elicit broadly
neutralizing Abs (bnAbs), which can neutralize and thus, pro-
tect against a large fraction of circulating viral strains (1–9).
A number of potent bnAbs have recently been isolated from
patients (10–15). In most cases, these bnAbs developed only after
years of chronic infection when the infecting strain had mutated
into a diverse viral population. Still, these cases prove that the hu-
man immune system can evolve bnAbs against HIV, and they raise
the exciting possibility that rationally designed immunogens and
immunization protocols may be able to elicit bnAbs efficiently in
diverse people.
After natural infection or vaccination, Abs are produced by a
Darwinian evolutionary process called affinity maturation (AM)
(16). Naive B cells are activated by productive interactions be-
tween their B-cell receptors (BCRs) and the immunogen- or
pathogen-derived antigen (Ag). These activated B cells then
seed structures called germinal centers (GCs), where they
replicate and undergo AM. Mutations are introduced into the
BCRs followed by an affinity-based competition for selection
and survival of the B cells. Multiple rounds of mutation and
selection occur, resulting in B cells with BCRs that bind to the
Ag with increasingly higher affinity as AM ensues. Plasma B
cells secrete Abs, which are modified forms of the BCR. There
is a growing consensus that guiding this Darwinian evolutionary
process toward the production of bnAbs will require immunization
with an Ag that activates the correct germline B cells (17–21)
followed by multiple variant Ags that share a set of conserved
residues and mimic the HIV viral spike (3, 6, 8, 20, 22).
If one must immunize with multiple variant Ags, there are at
least three major questions to address. (i) What form should the
variant Ags take so that AM can be steered toward evolving bnAbs?
(ii) In what temporal order (e.g., as a mixture, sequentially, or
in other permutations) should the variant Ags be administered?
(iii) What should be the concentrations of the variant Ags? Answers
to these questions are drawn from a large space of possibilities.
Mechanistic understanding of AM could serve as a guide, but
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how AM occurs when there are multiple variant Ags is poorly
understood. Important advances are being made to trace bnAb
evolution during natural infection (23–28) and find conditions
and immunogens that can induce bnAbs (7, 19, 29). However,
even if empirical sampling of conditions leads to success, this
advance would not provide design rules that could be used to
rationally optimize protocols to be effective in diverse people
and provide information pertinent for other highly mutable
pathogens. Thus, there is a role for modeling and simulation to
complement fundamental and applied experimental efforts on
this topic.
Building on earlier modeling and simulation of AM with a
single Ag (30–32), a few relevant studies with multiple Ags have
been reported. Chaudhury et al. (33) studied the generation of
protective and cross-reactive Abs against diverse strains of malaria
on immunization with a few strains. The malaria apical membrane
has a cluster of conserved epitopes (binding targets for B cells) and
a cluster of highly variable ones. Thus, the authors studied a situ-
ation where each Ag was composed of a single conserved epitope
(shared by all Ags) and one variable epitope. They found that im-
munization with multiple Ags enhances the fraction of B cells that
target the conserved epitope (compared with the use of one Ag)
and importantly, also enhances the development of Abs that are
more cross-reactive to the variable epitopes. Thus, the polyclonal
response from all Abs together results in a protective response to
multiple strains. Notice that, in the model used in ref. 33, which may
be realistic for malaria, epitopes are composed of either purely
conserved residues or variable residues.
Motivated by the challenge of inducing bnAbs against HIV,
Wang et al. (34) developed a computational model of AM in the
presence of multiple variant Ags and studied the relative effi-
cacy of different temporal patterns of immunization. They
reported that immunization with a mixture of variant Ags sep-
arated by relatively large mutational distances led to production
of low Ab titers and low breadth. This result occurred, because
the different variant Ags represent potentially conflicting se-
lection forces that can severely frustrate the Darwinian evolu-
tionary process of AM. This frustration can be alleviated by
varying the Ag concentration and changing other conditions.
Abs are then produced in greater quantities, but they still exhibit
low breadth. Wang et al. (34) found that the probability of in-
ducing cross-reactive Abs was improved by sequential immuni-
zation with the same variant Ags that produced Abs with low
breadth when presented as a mixture. These in silico predictions
were tested in model experiments in mice. A recent report (35)
provides further experimental support for this strategy.
Luo and Perelson (36) subsequently reported that, during the
coevolution of viral strains and Ab responses after infection, Ab
breadth increased with the number of variant Ags and the muta-
tional distances separating them. This result likely reflects the fact
that, like Chaudhury et al. (33), Luo and Perelson (36) assume that
there is one conserved epitope shared by all Ags, different Ags
contain distinct epitopes composed of variable residues only, and B
cells target either the conserved epitope or a variable epitope. The
authors considered broadly cross-reactive Abs to be those with high
affinity for the conserved epitope. The structure of the HIV viral
spike (37–39) indicates that the conserved residues, such as those
that are part of the CD4 binding site, are surrounded by highly
variable residues and protective glycans, which can be part of an
epitope that also contains the conserved residues [such as is the
case in the study by Wang et al. (34)]. Childs et al. (40) also studied
a problem pertinent to the development of cross-reactive Abs.
They reported that, in the presence of multiple antigenic sites, the
breadth of the Abs that evolve is reduced, which is consistent with
the findings in ref. 34.
In this paper, we develop analytical and computational models
of AM on immunization with a mixture of variant Ags in diverse
situations. We study the evolution of Ab breadth across a wide range
of conditions, including the number of Ags, their concentration, and
the mutational distances separating them. Based on our results, we
elaborate a principle of optimal frustration of the AM process:
an intermediate level of conflict between the selection forces
represented by the multiple variant Ags maximizes the probability
of evolving bnAbs. We also describe the biological reasons for the
existence of this optimum and how it is influenced by the variables
that we study. Our simulations exhibit some of the qualitative be-
havior observed during the course of natural infection (23–27) and
in laboratory studies of AM (41, 42). Finally, we discuss how our
results may provide conceptual guidelines for the design of optimal
immunization protocols to elicit bnAbs to HIV and other highly
mutable pathogens.
Model
Our model for BCRs, Ags, and the interactions between them is
coarse-grained and lacks atomic resolution. In the past, we have
used string models of BCRs and Ags augmented by nonlocal
interactions (34), and others have used string models without
such couplings (36). Here, we use a model that is further coarse-
grained following the seminal work of Perelson and Oster (43).
BCRs and Ags are points in a Euclidean vector space or shape
space. Each dimension represents one or more amino acids
composing the BCRs and Ags (Fig. 1). Coordinates correspond
to biochemical properties relevant for protein interactions, like
hydrophobicity or polarity. Perelson and Oster (43) recommend
5–10 dimensions to reflect the size of the Ab repertoire. Addi-
tional theoretical considerations and comparisons with immu-
nological data suggest five to eight dimensions (44, 45).
This shape-space representation captures the specificity of
BCR–Ag interactions. BCRs near an Ag have complementary
characteristics that allow them to bind strongly, whereas those
Fig. 1. A 2D shape space is sketched for illustration. There is one variable
dimension along the horizontal axis and one conserved dimension along the
vertical axis: Nd = 2,   Nv = 1,   Nc = 1. Five Ags are shown as red diamonds. They
are on the variable axis, where their identical conserved coordinate (zero)
represents conserved amino acids shared by all. Five initial germline or
founder BCRs are drawn as blue Y shapes distributed randomly on a
hypersphere (dashed circle) centered at the origin. As AM proceeds, BCRs
move within this space by mutating, and those moving closer to the Ags are
preferentially selected.
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far away bind weakly. We make this precise by defining the
binding free energy E as
E
kBT
=
1
Nd
kr− ak2, [1]
where Nd is the shape-space dimensionality, r and a are the
coordinates of the BCR and Ag, and k. k denotes the Euclidian
distance between them. The free energy is expressed in units of
the thermal energy, kBT. The strongest possible binding corre-
sponds to E= 0, when the BCR and Ag overlap exactly, whereas
larger positive values of E represent weaker interactions.
It is often more natural to describe strong binding in terms of
high (positive) affinity, and therefore, we define affinity as
A=Ea −E, where Ea is a reference free energy that sets the
binding threshold for activation. The equilibrium constant for
BCR–Ag binding, Ka, is given by
Ka = exp

−ðE−EaÞ
kBT

= exp 

A
kBT

. [2]
We set Ea = 8kBT ≈ 4.9  kcal  mol−1, so that Ka may increase
nearly 3,000-fold during AM (46) as B cells evolve from barely
meeting the activation threshold (E≈Ea,A≈ 0) to binding as
strongly as allowed by Eq. 1 (E≈ 0,A≈ 8kBT).
Ag Variability.A few structural elements on the HIV envelope are
conserved across the viral population and present immunogenic
epitopes for BCRs (39). Germline B cells that can target such epi-
topes have a chance to evolve into bnAbs, and recent studies have
shown how designed immunogens can activate such cells (17–21).
We study how these germline B cells might evolve on immunization
with different types of mixtures of variant Ags. The conserved resi-
dues are surrounded by highly variable residues and glycans that can
be part of the epitope to which a BCR binds.
The variant Ags that we consider share a set of conserved
residues but have nonoverlapping mutations in the variable residues
that surround the conserved residues. In our shape space, we select
the first Nv dimensions to be variable (generated stochastically for
all Ags) and the remaining Nc =Nd −Nv dimensions to be con-
served (identical for all Ags). Conserved and variable regions reside
on the same epitope, and BCRs can span both regions, such as with
most epitopes targeted by bnAbs for HIV (4, 6).
Variable coordinates are distributed independently with
probability density
PðaiÞ=φðai; 0, σvÞ  for  i∈ f1, . . . ,Nvg, [3]
where φðai; 0, σvÞ is the normal density function with mean zero
and variance σ2v. All conserved coordinates reside at the center of
shape space:
ai = 0  for  i∈ fNv + 1, . . . ,Ndg. [4]
The multidimensional distribution of Ag coordinates is then
PðaÞ=
"YNv
i=1
φðai; 0, σvÞ
#" YNd
i=Nv+1
δðaiÞ
#
, [5]
where δðaiÞ is the Dirac delta function. Taken with the binding
free energy from Eq. 1, this coordinate distribution defines a
characteristic energy scale for viral mutations:
Ev
kBT
=
1
Nd
a2=Nv
Nd
σ2v . [6]
BCRs that match one viral variant perfectly will bind other mutant
strains with a free energy that is typically weaker on the order of Ev.
Values of Ev ≈ 2kBT ≈ 1.2  kcal  mol−1 correspond approximately to
Ags that differ by mutations in one or two amino acids (SI Appen-
dix, Fig. S1). Below, we study the effects of varying the number of
Ags and the mutational distances between them, where we vary the
mutational distance by changing the value of Ev.
BCR Mutation. High-affinity Abs evolve during AM through a series
of mutations in the BCRs. We represent mutations as displacements
Δr from the previous receptor coordinate r:
rðg+1Þ = rðgÞ +ΔrðgÞ, [7]
where superscripts denote the B-cell generation. The displace-
ments are drawn from an independent and identically distributed
normal distribution:
PðΔrÞ=
YNd
i=1
φðΔri; 0, σmÞ, [8]
where φðx; 0, σmÞ is the normal density function with mean zero
and variance σ2m.
This formulation of BCR mutation, together with Eq. 1, repro-
duces two important features of protein interactions. Consider
a receptor r and Ag a with binding free energy E. On mutation
Δr, the expected change in binding free energy is
ΔEm
kBT

=
1
Nd
D
kr+Δr− ak2 − kr− ak2
E
= σ2m. [9]
The mean change in binding free energy is always positive
(reflecting weaker binding) and independent of the initial BCR
structure. Previous models of AM (30, 34) have reproduced these
characteristics to match data from the protein interaction (PINT)
database (47). We choose σm = 1, so that hΔEmi= kBT ≈
0.62  kcal  mol−1, corresponding approximately to single-amino acid
mutations as quantified by refs. 47 and 48 (SI Appendix, Fig. S1).
GC Simulation.We simulate AM in a GC (16) with the steps below.
The model parameters are summarized in SI Appendix, Tables S1
and S2. Our qualitative conclusions are robust with respect to the
parameters chosen as shown in SI Appendix, Figs. S4–S10.
Step 1: Specify the number of variable and conserved shape-
space dimensions, Nv and Nc. In the text, we present results for
Nv =Nc = 4. Other choices produce qualitatively similar results
(SI Appendix, Figs. S4 and S5).
Step 2: Specify the concentration cAg of each immunizing variant
Ag in the GC (equal for all Ags and constant through time).
Step 3: Specify a mutational variability, which corresponds to
an average mutational distance separating the variant Ags, by
setting the energy scale Ev defined by Eq. 6.
Step 4: Generate NAg variant Ags with shape-space coordi-
nates drawn from Eq. 5 and present them as a mixture.
Step 5: Seed the GC with Nf = 5 founder B cells placed ran-
domly on a hypersphere centered at the origin of the shape
space (Fig. 1). The radius is specified in terms of the binding
energy Ef of a founder cell for Ags at the origin. We choose
Ef =Ea = 8kBT, so that founders just meet the activation
threshold. Using Eq. 1, we translate the energy into a radius:
rf =
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
NdEa=kBT
p
=
ﬃﬃﬃﬃﬃﬃﬃﬃ
8Nd
p
. Recent imaging studies suggest that
the number of founders may be larger (49), and therefore, we
studied the effect of varying Nf and found that the qualitative
conclusions remained unchanged (SI Appendix, Fig. S6).
Step 6: Replicate the founder B cells without mutation to gener-
ate a total GC population of 1,500 B cells (50).
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Step 7: Simulate the Darwinian evolution of B cells through
the iterative processes of selection and mutation implemented
in steps 8 to 12 below.
Step 8: For each B cell, indexed by j, simulate Ag binding
under two scenarios of Ag presentation by follicular dendritic
cells (FDCs). In the first scenario, which we call see one, the
Ag distribution on FDCs is heterogeneous, and therefore,
each B cell encounters only one Ag variant chosen randomly
in each round of selection. In the second scenario, named see
all, Ags are distributed homogeneously on FDCs, and B cells
encounter all Ag variants on every round of selection. These
two limiting cases should encompass the true biological con-
ditions.
These scenarios can be defined by the set K of Ag variants
encountered by B cell j on this round of selection. Under the see
one scenario, K contains only a single element chosen at random.
This stochastic selection is made independently for each B cell at
each round of selection. Under the see all scenario,K contains all
Ags: K= f1, . . . ,NAgg. With this Ag set, the simulation of bind-
ing proceeds as follows.
i) Compute the total amount of Ag bound:
qj = cAg
X
k∈K
  Kjk. [10]
The index k identifies immunizing Ags, and
Kjk = exp

−


Ejk −Ea

kBT

, [11]
with
Ejk
kBT
=
1
Nd
rj − ak2, [12]
where rj and ak are BCR and Ag coordinates.
ii) Allow the B cell to successfully internalize Ag with probability
pj =
qj
1+ qj
=
cAg
P
k∈K
Kjk
1+ cAg
P
k∈K
Kjk
. [13]
Otherwise (with probability 1− pj), the B cell dies by apo-
ptosis and is removed (30, 34).
Step 9: Simulate competition for T follicular helper (Tfh) cells.
Rank the remaining B cells by qj, which should be monoton-
ically related to the amount of Ag bound in step 8. The frac-
tion f  Tfh = 0.7 having the largest qj receives Tfh help and
survives; the others die by apoptosis. This deterministic rule
ignores a stochastic element introduced by the search for Tfh
cells (32). Other values of f  Tfh yield qualitatively similar results
(SI Appendix, Fig. S7).
Step 10: With probability pmem = 0.05, classify remaining B
cells as memory cells and remove them from the GC.
Step 11: With probability ppla = 0.05, classify remaining B cells with
affinity of at least Apla = 4kBT for the Ag bound in step 8 as Ab-
secreting plasma cells and remove them. Applying a threshold
ensures that Abs have high affinity for at least one Ag (51).
Step 12: Divide remaining B cells into two daughter cells,
which mutate independently with probability μ= 0.5. Muta-
tions are lethal, and daughter cells are removed, with proba-
bility plet = 0.3. Mutations alter affinity, and the BCR evolves
stochastically according to Eq. 8, with probability pa−a = 0.2;
otherwise, mutations are silent, and the BCR is unchanged
(30, 34, 52, 53).
Step 13: Repeat steps 8–12 (one round of selection and muta-
tion) until (i) no B cells remain and the GC is extinguished, (ii)
the number of surviving B cells surpasses the initial size after
founder replication (simulating Ag consumption), or (iii) the
number of cycles reaches 100 (simulating Ag decay to low levels).
Step 14: Generate 104 viral challengers with coordinates
drawn from Eqs. 5 and 6 with mutational variability EðCÞv =
2kBT ≈ 1.2  kcal  mol−1, where the superscript (C) distinguishes
the variability of the challenger Ags from the immunizing Ag
variability. This energy scale corresponds to mutations in a
few amino acids (47, 48) and is consistent with the typical
variability in HIV-1 epitopes targeted by bnAbs (23, 25, 27).
Other choices for challenger diversity yield qualitatively simi-
lar results (SI Appendix, Fig. S8).
Step 15: For each Ab, compute its affinity for each challenger and
define the neutralization breadth as the fraction of challengers to
which the Ab binds with affinity exceeding Aneut = 5kBT. Numer-
ical values of breadth depend on the threshold chosen, but the
rank ordering of immunization protocols (e.g., which is best) is
independent of this choice (SI Appendix, Fig. S9).
Step 16: Run additional independent AM trajectories (steps 4–15)
until 105 or more Ab-secreting plasma cells are collected for each
case studied to ensure sufficient statistical accuracy when averag-
ing over the Ab population to determine the breadth of coverage.
Results
The breadth of an Ab increases monotonically with its average
affinity for viral variants (SI Appendix, Fig. S11). Strain-specific
Abs may have very strong affinity for one particular Ag, but
bnAbs will have higher affinity when averaged across the spec-
trum of viral mutants.
The mean binding free energy for a BCR at coordinate r,
averaged over an Ag distribution PðaÞ, is
hEðrÞi
kBT
=
1
Nd
Z
a
kr− ak2PðaÞda. [14]
Substituting the separable distribution from Eq. 5 yields
hEðrÞi
kBT
=
1
Nd
krk2 +Nv
Nd
σ2v . [15]
Receptors at the origin in shape space (minimizing krk2) have
the highest average affinity (lowest hEi) (Eq. 2) and highest
breadth. Receptors near the origin have optimal binding with
conserved Ag residues, which allows them to have some favor-
able interactions with all Ags. They have also reached the center
of the distribution of variable residues. Thus, they may not bind
strongly with the variable region of any single variant Ag, but in a
compromise of sorts, they do not have strongly unfavorable in-
teractions that abrogate recognition.
The second term in Eq. 15 depends only on characteristics of
the Ag distribution. It is independent of receptor structure and
therefore, cannot be optimized by vaccination. This result implies
that pathogens with greater diversity, quantified by either the
fraction of the genome that is variable (Nv=Nd) or the diversity
within the variable regions (σv), will elicit Abs with lower breadth
regardless of the immunization protocol.
Optimal Number of Ags Leads to Maximal Breadth. Fig. 2 illustrates
the variation of key characteristics of Abs produced by immuni-
zation with mixtures containing different numbers of Ag variants.
E7042 | www.pnas.org/cgi/doi/10.1073/pnas.1614940113 Shaffer et al.
Ag coordinates are chosen from the probability distribution in
Eqs. 5 and 6, with the same average mutational distance between
variant Ags, regardless of the number of Ags. The concentration per
Ag (cAg from Eq. 13) is fixed at 0.2, and B cells encounter only one
Ag at each round of selection (the see one scenario in step 8 above).
Ab characteristics are averaged over a population of 105 or more
plasma cells produced by thousands of independent AM trials.
At the concentration simulated (and for other parameters in
our model), breadth is maximized for four to six Ags (Fig. 2A),
which also corresponds to a maximum in the number of somatic
mutations (Fig. 2B) and average affinity for “challenger” Ags that
represent the full population of viral variants (Fig. 2C). With a
single Ag, the B cells most likely to survive the competition during
AM are those with mutations that drive them closest to the single
immunizing Ag that they see in the GC. The resulting Abs have very
high affinity for that one target, but that specificity for one specific
variable Ag structure results in low average affinity and low breadth
(Fig. 2) across the full spectrum of viral variants (the challenger
Ags). As the number of Ags increases, B cells sacrifice some affinity
for the specific targets presented by the immunogens and instead,
develop moderate affinity for a broader range of Ags through ad-
ditional mutations that focus Ab binding to the conserved residues
and minimize interactions with the variable residues.
As the number of Ags increases beyond six, the breadth de-
creases along with the number of mutations and affinity for both
immunizing and challenger Ags. As noted by Wang et al. (34),
when B cells encounter only one type of Ag during each in-
teraction with FDCs, the multiple variant Ags in the GC present
potentially conflicting selection forces that can frustrate AM.
Because B cells are likely to encounter different Ags on suc-
cessive rounds of mutation and selection, the normal course of
AM is disrupted, because it is difficult to be positively selected in
successive cycles.
After immunization with a single Ag, frustration is absent, and
B cells easily evolve high affinity for that single Ag. Strain-specific Abs
of low breadth are produced, because there is no driving force for the
Darwinian evolutionary process of AM to evolve cross-reactive Abs.
As shown in Fig. 3, under these conditions of low frustration, very few
GCs are extinguished because of apoptosis of all B cells. As the
number of variant Ags increases, the frustration level increases, and
there is an evolutionary driving force that favors the development of
cross-reactive B cells. However, the increasing frustration also results
in the extinction of a higher fraction of GCs (Fig. 3) because of the
increasing likelihood that a population of B cells undergoing AM will
be unable to survive owing to the potentially conflicting selection
forces. In the GCs that are not extinguished, unlike when there is only
one immunizing Ag, the population of B cells does not rise rapidly,
fill up the GC, and consume all of the Ag. This behavior occurs
because many B cells are not sufficiently cross-reactive to survive
successive rounds of mutation and selection. For the B cells that do
survive, AM continues for a relatively long time, thus enabling them
to acquire the many mutations required for cross-reactive B cells to
evolve. Thus, as the number of variant Ags increases, there is an
increase in the fraction of GC reactions that reach the maximum time
allowed in our simulations (a proxy for Ag decay). Correspondingly,
the number of mutations evolved and breadth of the Abs increase
(Fig. 2). As the number of variant Ags increases further, however, the
level of frustration becomes too high, most GCs extinguish (Fig. 3),
and low titers of Abs exhibiting low breadth result.
This last situation was previously described by Wang et al.
(34). Because of differences in the model for BCR–Ag affinity,
the high frustration limit emerged in the work in ref. 34 at lower
Ag numbers. For the immunization protocols and conditions that
lead to the results shown in Fig. 2, the level of frustration pro-
gressively increases with the number of variant Ags used in the
immunogen. In this case, the probability of evolving bnAbs is
maximized at an intermediate level of frustration.
Fig. 4 shows results for the scenario in which all types of Ags
are encountered simultaneously during B cell–FDC interactions
(the see all scenario in step 8 above); otherwise, conditions are
identical to Fig. 2. Each B cell can potentially be positively selected
by binding the same variant Ag in every cycle, and therefore, the
frustration is substantially alleviated compared with the case where
only one type of variant Ag is encountered in every cycle. As a
consequence, strain-specific Abs are likely to emerge. Thus, the
breadth of Abs produced is substantially lower compared with the
case where only one type of Ag is encountered at a time.
In our model, during each round of mutation and selection, a
B cell has only one chance to interact with FDCs, and the total
amount of Ag bound and internalized is given by Eq. 10. In re-
ality, B cells have several chances to interact with FDCs sepa-
rated by refractory periods (54). Eq. 10 is approximate and may
well capture the effects of multiple opportunities to interact with
FDCs. If it does not, then the case where only one type of Ag is
encountered in every B cell–FDC interaction but between re-
fractory periods, there are enough opportunities for a B cell to
interact with all types of Ags in a single cycle is similar to the
situation when all types of Ags are encountered during every
round of selection (but with one B cell–FDC interaction per
cycle). An example may be when there are very few types of
variant Ags and there are multiple opportunities to be positively
selected. Of course, in such a case, the frustration is alleviated,
and strain-specific Abs will likely result. The frustration can be
increased by lowering the Ag concentration.
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Fig. 2. Optimal Ag number. The immunization protocol uses an Ag mixture at
a fixed concentration (cAg = 0.2) and mutational variability (Ev =2kBT). In these
simulations, B cells encounter only one randomly chosen Ag at each round of
mutation and selection. (A) Neutralization breadth, averaged over the Ab
population, is largest when the immunogens are composed of four to six Ags.
(B) The number of mutations accumulated by Ab-secreting plasma cells is
strongly correlated with breadth: Abs with the highest breadth have the most
mutations. (C) The average affinity for challenger Ags, the wide range of viral
mutants used to evaluate breadth, is also strongly correlated with breadth.
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Optimal Ag Concentration Leads to Maximal Breadth. The Ag con-
centration in the GC, which we assume to be proportional to the
immunization dosage, plays a major role in determining the survival
probability of B cells. Fig. 5 shows neutralization breadth, averaged
over 105 Abs, for NAg = 1, 4, and 20 variant-immunizing Ags as a
function of the total Ag concentration, NAgcAg. As before, the av-
erage mutational distance between variant Ags is independent of
their number.
For each Ag number, breadth reaches a maximum at a par-
ticular Ag concentration, a result also noted by Wang et al.
(34). Far below the optimum, the probability of productive
binding to an Ag (proportional to concentration in Eq. 10) is
low, B-cell survival probability is small, most B cells quickly die
by apoptosis after failing to bind sufficient Ag for survival, and
the GC extinguishes before the maturing B cells accumulate
sufficient mutations to acquire breadth. Well above the opti-
mal concentration, the probability of productive Ag binding
is large for all B cells, survival probabilities are high, and the
GC reaction terminates quickly as the B cells proliferate and
consume all Ag. Again, too few mutations accumulate to
acquire breadth.
The maximum breadth increases with the number of Ags, but
the concentration required to achieve that maximum also in-
creases with NAg. This correlation occurs because the degree of
frustration increases as NAg increases, requiring higher Ag con-
centration to alleviate the frustration. More detailed examina-
tion (SI Appendix, Fig. S2) shows that the optimal total Ag
concentration increases quadratically with NAg. The high doses
required for large Ag numbers may be impractical, or the cor-
responding Ag concentration within GCs may be biologically
unrealistic. It may also be difficult to achieve the relatively low
concentrations required for breadth to evolve for smaller Ag
numbers (4–6) near the optimum shown in Fig. 2.
Increasing the Number of Ags While Decreasing Their Mutational
Distance Reduces the Dependence on Ag Concentration. We ex-
plored whether the pragmatic difficulties associated with the
strong optimal concentration dependence on the number of Ags
can be overcome by decreasing the mutational distance between
the immunizing variant Ags as their number increases. To this
end, we specify the following inverse relationship between mu-
tational variation and Ag number:
Ev
kBT
=
λ
NAg
, [16]
where the constant λ is the largest Ag count that we wish to
consider. With this restriction, immunization with the most var-
iant Ags, NAg = λ, corresponds to the smallest mutational vari-
ability between them. The parameters are such that this choice
generates the smallest mutational distance that is biologically
relevant, Ev = kBT ≈ 0.62  kcal  mol−1, corresponding approxi-
mately to mutations in single amino acids (SI Appendix, Fig. S1).
Fig. 6 shows that, in this case as well, there is an optimal
number of Ags (and corresponding mutational distance between
Ags) that results in maximal breadth. The reason underlying the
optimum is different, however. When there are few Ags, the level of
frustration is very low, and Abs with low breadth are produced.
Frustration increases as the number of immunizing variant Ags
grows, leading to increased breadth. However, as the number of
variant Ags increases further, the level of frustration is also allevi-
ated, because the variant Ags are also closer to each other in mu-
tational distance. If the number of Ags becomes too high (and
mutational distance between them becomes sufficiently small), then
the frustration level is quite low. Frustration is low because in
subsequent rounds of selection, a given B cell will interact with very
similar Ags. Thus, above a threshold number of Ags, the breadth
begins to decline. Therefore, in this case, as we increase NAg, we
traverse conditions ranging from low frustration to intermediate
frustration to low frustration again. This temporal pattern is made
vivid in Fig. 7, where we see that the fraction of GCs that extinguish
after apoptosis of all B cells and the fraction that survive until Ag
has decayed both exhibit a maximum at intermediate numbers of
variant Ags. This behavior is in contrast to Fig. 2, where increasing
NAg corresponds to traversing conditions that range from low
frustration to intermediate frustration to high frustration. In both
types of immunization protocols, an intermediate level of frustra-
tion maximizes the probability of evolving bnAbs.
Fig. 8 shows that, when the mutational distance between im-
munizing variant Ags is reduced as their number increases, the
sensitivity of the optimal concentration to the number of Ags
is much reduced, as is the required Ag concentration (compare
Fig. 8 with Fig. 5). This reduction occurs because rather than
increasing concentration to alleviate frustration, we are achieving
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Fig. 3. GC fate as a metric of frustration. Conditions are identical to
those in Fig. 2. Among the thousands of independent AM trajectories, we
show the fraction of GCs that extinguish after apoptosis of all B cells (red
triangles) and the fraction that survive until all Ag has decayed (black
circles). The remaining GCs (not shown) rapidly fill with proliferating B
cells and terminate after consuming all Ag as described in step 13 in GC
Simulation.
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Fig. 4. Comparison of breadth for see one vs. see all Ag presentation by
FDCs. Conditions are identical to those in Fig. 2, with the exception of Ag pre-
sentation by FDCs. The legend indicates whether the B cells interact with only
one Ag (selected randomly) or all Ags at each cycle of the GC reaction. Frus-
tration during AM is reduced when B cells interact with all Ags on each round of
selection, and breadth is lower as strain-specific Abs emerge in this case.
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this goal by decreasing the mutational distance between Ags. The
lower sensitivity to Ag concentration may be practically important,
because it may be difficult to precisely control the amount of Ag
expressed on FDCs. Our results suggest that an optimal number of
immunizing variant Ags with an optimal mutational variability can
be chosen to maximize the chance of evolving bnAbs across a
relatively broad range of Ag dose.
Principle of Optimal Frustration. The essential origin of optimal
conditions resulting in maximal breadth is easy to understand.
During each cycle of selection, division, and mutation, each B cell
can undergo one of four possible fates: (i) it can fail to be selected
and die by apoptosis, (ii) it can be positively selected and divide into
two identical cells, (iii) it can be positively selected and divide into
one mutated daughter cell and one identical cell, and (iv) it can be
positively selected and divide into two mutated daughter cells. Let
the probability of positive selection be ps and the probability (per
cycle) of mutation be μ. The probability of the first possibility is
1− ps, the second is psð1− μÞ2, the third is 2psμð1− μÞ, and the fourth
is psμ2 (SI Appendix). The probability of positive selection depends
on the BCR and the other conditions that determine the degree of
frustration: the number of Ags, their concentration, the mutational
distance between them, and how many types of Ag are encountered
at each round.
If the extent of frustration is large, apoptosis is the likely
outcome (ps is small), most B cells will die, and the GC will be
rapidly extinguished. This situation will produce few Abs and
bnAbs. If the degree of frustration is small (when Ag concen-
tration is high, when NAg is large and the mutational distance
separating the Ags is small, or when all types of Ags are en-
countered in every B cell–FDC interaction), then positive se-
lection is likely (ps is large). Now, because the mutation
probability (μ) is much less than one, the GC will rapidly be
populated by B cells that have not acquired the number of mu-
tations required to confer breadth by the time that all Ag has
been consumed. This situation will not result in bnAbs either but
rather, strain-specific Abs. Only when the conditions lead to
intermediate levels of frustration (intermediate values of ps) will
the GC reaction continue long enough for the B cells to acquire
the number of mutations required for bnAbs to develop. Nu-
merical solutions of this model show that an optimal value of ps
naturally emerges (SI Appendix).
In short, an optimal level of frustration leads to maximal
breadth. In our calculations, this optimal frustration manifested
as an optimal number of Ags, an optimal mutational distance
separating Ags, and as previously described (34), an optimal Ag
concentration. In the language of dynamical systems, there are
two strong attractors for the dynamical processes occurring in
the GC when multiple variant Ags are part of the immunogen:
one that corresponds to apoptosis when the frustration level is
too high, and one that corresponds to strain-specific Abs when
the extent of frustration is too low. Perhaps, a narrow ridge line
leads to the attractor corresponding to bnAbs. [The sharpness of
the maximum does indeed suggest a strong sensitivity to the level
of frustration and a narrow region of bnAb production (SI Ap-
pendix, Fig. S3).] Future research, both experimental and theo-
retical, aims to determine how to design immunization protocols
that will stabilize B cells as they traverse this ridge line to reach
the bnAb attractor with high probability.
Dead-End and Off-Track Abs. Most bnAbs accumulate many mu-
tations during AM (6, 55). For example, Bhiman et al. (27) ob-
serve high degrees of somatic hypermutation (SHM) in their
bnAb lineage. In addition, however, they and others (13, 56–58)
find two other Ab classes: “off-track” Abs with the same large
number of mutations but low breadth and “dead-end” Abs with
few mutations and low breadth. Similar findings have been
reported for Abs to the influenza virus (59).
Our simulations also produce dead-end and off-track Abs, as
shown in Fig. 9. We collect Abs from simulations that generate
bnAbs (identical to those in Fig. 2 with NAg = 5), count the number
of mutations from the germline, and separate the sample into those
with four or fewer (Fig. 9A) and seven or more mutations (Fig. 9B
and SI Appendix, Fig. S14). In set A, the developing Abs could not
tolerate the diversity of variant immunizing Ags, failed to evolve
beyond four mutations from the germline, and have breadth below
0.3. In set B, the Abs have accumulated at least seven mutations.
Nearly 60% of Abs with this high degree of SHM are broadly
neutralizing, with breadth greater than 0.5. Five percent, however,
have breadth below 0.2, despite significant evolution from the
germline. Note that these results reflect the different ways in which
the same germline B cells evolved under identical conditions,
resulting in bnAbs but also, off-track and dead-end Abs. The
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Fig. 5. Optimal Ag concentration. Conditions are identical to those in Fig. 2,
except that Ag concentration is varied over a wide range. The legend indi-
cates the number of Ags, NAg, administered as a mixture, and the mean
neutralization breadth is plotted against the total Ag concentration, the
product NAgcAg. For each Ag count, the induced Ab breadth reaches a
maximum at an optimal Ag concentration.
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Fig. 6. Optimal Ag number and mutational variability. Ags are adminis-
tered as a mixture with fixed concentration (cAg = 10); the mutational dis-
tance between Ags varies inversely with their number (according to Eq. 16
with λ= 20). The outer x axis shows the number of Ags increasing from left to
right; the inner x axis shows the mutational distance between them de-
creasing from left to right. Breadth is maximized at an intermediate number
of Ags and mutational distance.
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production of off-track and dead-end Abs is a consequence of the
intrinsically stochastic character of evolutionary processes and may
be difficult to eliminate by tuning immunization strategies.
Discussion
The development of vaccination strategies that can elicit bnAbs
against diverse strains of highly mutable pathogens would have a
significant impact on global health. Enormous advances are be-
ing made in isolating bnAbs against HIV from patients (10–15),
understanding the evolutionary pathways that lead to bnAbs in
individuals (23–28), and developing immunogens to activate the
germline B cells that can mature into bnAbs (17–21, 35). Lab-
oratories have synthesized structures, such as stabilized envelope
trimer variants, that aim to mimic the trimeric viral spike and can
contain customized mutations, thus creating variant Ags that
share conserved residues (29, 60, 61).
On activation of the correct germline B cells, what should be the
temporal pattern of immunization with the variant Ags, their num-
ber, concentrations, and mutational separation to optimally induce
bnAbs? We and others have suggested sequential immunization with
variant Ags as one solution (3, 6, 8, 20, 22, 34). Our past work leading
to this conclusion considered variant Ags separated by relatively large
mutational distances. In this circumstance, we found that temporal
separation of the potentially conflicting selection forces represented
by the variant Ags had a greater chance of inducing bnAbs compared
with immunization with a mixture of the same Ags. In this paper, we
studied the possibility of evolving bnAbs on immunization with a
mixture of variant Ags across a wide range of conditions.
Our principal findings are as follows. If the average mutational
distance between immunizing variant Ags is fixed, an optimal
number of Ags maximizes the probability of eliciting bnAbs. In
this case, there is also an optimal Ag concentration, and it is a
very strong function of the number of immunizing Ags. If we
reduce the mutational distance between Ags as their number
increases, we also find that there exists an optimal number of
Ags separated by an optimal mutational distance. In this case,
there is only a modest dependence of the optimal Ag concen-
tration on the number of variant Ags. The reduced concentration
dependence is a practical advantage, because Ag concentration
in GCs is difficult to control by manipulating the Ag dose in an
injected vaccine. Our findings for a few Ags separated by many
mutations (Fig. 6 with NAg ≤ 4) are qualitatively consistent with
those obtained by Wang et al. (34) using a more detailed string
model of BCR and Ag structure, which is expected to yield
quantitatively different results (31).
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Fig. 7. GC fate as a metric of frustration. Conditions are identical to those in
Fig. 6. The outer x axis shows the number of Ags increasing from left to right;
the inner x axis shows the mutational distance between them decreasing from
left to right. The fraction of GCs that extinguish after apoptosis of all B cells, a
proxy for the level of frustration during AM, is nonmonotonic, reaching a
maximum at an intermediate number of Ags and mutational distance.
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Fig. 8. Optimal total concentration. The legend indicates the number of Ags,
NAg, administered as a mixture. The mutational distance between Ags varies
inversely with NAg according to Eq. 16 with λ= 20. The mean neutralization
breadth is plotted against the total Ag concentration, the product NAgcAg. The
optimal total concentration is much less sensitive to NAg when mutational vari-
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Fig. 9. Dead-end and off-track Abs. The histogram shows the distribution of
neutralization breadth for Abs with (A) four or fewer and (B) seven or more
mutations produced in simulations with conditions identical to those in Fig. 2 and
NAg = 5. The ordinates are probability densities. Most Abs that reach an evolu-
tionary dead-end (A) have very low breadth. Most Abs with a high degree of SHM
(B) are broadly neutralizing, with breadth greater than 0.4, but a small subset of
off-track Abs has breadth below 0.2, despite having accumulated a large number
of mutations. SI Appendix, Fig. S14 shows the full distribution of mutations.
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The optimal conditions that we describe emerge when the level
of frustration because of the conflicting selection forces is neither
too high nor too low. When the frustration level is too low (e.g.,
many variant Ags separated by small mutational distances), strain-
specific Abs are likely to develop. If the frustration level is too high
(e.g., several variant Ags separated by large mutational distances),
AM cannot be sustained, and few Abs are produced. Only in-
termediate levels of frustration inhibit strain-specific Abs while
allowing B cells to survive enough rounds of selection to accu-
mulate the mutations required for breadth. We develop a simple
intuitive picture and model to describe this principle of optimal
frustration. We also show that, even in circumstances where bnAbs
are likely to emerge, dead-end and off-track Abs also develop (27).
It would be difficult to completely prevent the evolution of such
Abs by controlling vaccination protocols because of the inherently
stochastic character of the evolutionary process of AM.
A single mixture of optimally designed immunogens is more
appealing from a logistic and feasibility perspective than a se-
quence of distinct vaccines. An example of such a scheme aimed
at eliciting bnAbs targeting the V2 region of the Env trimer
(which is commonly targeted during infection) might be to use
stabilized envelope trimers (SOSIPs) from strains previously
shown to have enhanced interactions with the rare B cells that
mature into V2-directed bnAbs (39, 62). Thereafter, incorporation
of mutations within the V2 region would result in a mixture of
variant immunogens to drive tolerance of diversity. Immunization
with different numbers of SOSIP variants separated by different
mutational distances may be able to test the predictions that we
report in this paper.
After eliciting the correct germline B cells, the optimal strat-
egy for inducing bnAbs efficiently may require a combination of
immunization with a mixture of an optimal number of variant
Ags separated by an optimal mutational distance (Fig. 6) fol-
lowed by sequential immunization with variant Ags separated by
a larger mutational distance (3, 6, 8, 20, 22, 34). Alternatively,
the most efficient strategy may be sequential immunization fol-
lowed by a mixture of variant Ags, as in ref. 35. Study of these
situations to determine optimal conditions as we report here,
both computationally and experimentally, is an important di-
rection of future research. We also note that we have not con-
sidered the distracting epitopes (which are completely variable)
in addition to those that contain a conserved set of residues that
are present in immunogens, such as SOSIPs. It is unknown
whether eliciting the right germline B cells first is sufficient to
focus AM on these B cells that target epitopes that contain
conserved residues. Study of this issue is also warranted.
The mutations that separate the variant Ags must be in the
variable residues that are spatially adjacent to the conserved
residues that are shared between them. Where possible, the
immunogens should exhibit some affinity for the germline B cells
associated with bnAbs. In Fig. 6, we predict optimal breadth for
8–10 Ags separated by roughly three mutations. In earlier sim-
ulations of mixtures with model Ags, supported by model ex-
periments (34), variant Ags separated by 11 mutations did not
elicit bnAbs. We, therefore, expect optimal immunogens to
contain six to eight Ags with variation in 3–10 locations.
To further guide studies with trimeric variant Ags, such as SOSIP
mutants (29, 61), additional computational investigations are re-
quired. Specifically, a set of SOSIP Ags must first be chosen that
bears mutations in variable residues spatially adjacent to the con-
served part of the target epitope and that is the most mutable in the
circulating HIV population (63). Detailed atomistic molecular dy-
namics calculations must be performed with these mutants to as-
say the binding affinity of germline Abs [or Abs first induced by
germline-targeting immunogens (17–19)]. The subset that displays
weak to moderate affinity for at least one of the variants should
then be selected. Simulations, such as those reported in this paper
but now coupled to detailed atomistic calculations to compute
binding energies of mutated BCRs for these Ags before every
round of selection, should then be carried out to screen for the
best sets of variant Ags. Such studies are planned.
Finally, although our model was inspired by the problem of
inducing bnAbs against the HIV envelope, it is a coarse-grained
representation that is meant to reveal general principles and
may, therefore, also apply to other highly mutable viruses.
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